Aurinia Pharmaceuticals Inc. (AUPH) Trading Down 3.7%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s share price traded down 3.7% during mid-day trading on Thursday . The company traded as low as $2.26 and last traded at $2.35, with a volume of 1,531,332 shares changing hands. The stock had previously closed at $2.44.
A number of equities analysts recently issued reports on the stock. HC Wainwright increased their target price on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday. Canaccord Genuity reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, May 12th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. Leerink Swann reiterated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday. Finally, FBR & Co reiterated an “outperform” rating and issued a $9.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $7.75.
The firm’s market capitalization is $75.86 million. The firm’s 50 day moving average price is $3.14 and its 200 day moving average price is $2.78.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.